

# A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06716138

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Avistone Biotechnology Co., Ltd.
<b>Enrollment</b>	96 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Age e 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2
- Life expectancy e 12 weeks
- Measurable disease per RECIST v1.1
- Adequate organ and marrow function as defined in the protocol
- ... and 1 more (see full listing online)

### Exclusion (4)

- Active infection including tuberculosis and HBV, HCV or HIV
- Known active or untreated CNS metastases
- Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression
- Participants with serious cardiovascular or cerebrovascular diseases

## Locations (5 total)

---

Memorial Sloan Kettering Cancer Center, New York, New York, United States  
Research Site, Fuzhou, Fujian, China  
Research Site, Guangzhou, Guangdong, China  
... and 2 more locations